Hepatitis C Therapy

Results of first interim safety, antiviral analysis of HVC protease inhibitor reported

Published in Hepatitis Weekly, January 15th, 2007

Tibotec BVBA and Vertex Pharmaceuticals Incorporated (VRTX) announced results from a planned interim safety analysis from PROVE 1, an ongoing phase 2b clinical trial of the investigational hepatitis C virus (HCV) protease inhibitor telaprevir (VX-950).

Following an agreement earlier this year, Tibotec and Vertex are collaborating to develop telaprevir in Europe, South America, Australia, the Middle East, and selected Asian countries.

In accordance with the PROVE 1 study design, an interim safety and antiviral activity analysis has been conducted and the data have been reviewed by the independent data monitoring committee overseeing the trial. A total...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2007-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry